Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06806332

Glaucoma Drop Aids Part 2

Glaucoma medications are vital to disease management and prevention of further loss of vision as over time glaucoma will lead to irreversible blindness. The average size of a glaucoma medication bottle is around 10cc and these medications when used 2-3 times daily are expected to last patients an entire month. The investigators found that at Boston Medical Center (BMC) a majority of Yawkey Eye Clinic patients are unable to deliver the drops into their eyes due to poor vision or difficulty squeezing drop bottles. These patients also often deliver more than a necessary amount leading to premature completion of the bottle. However, because the cost benefit ratio of these drop aids is unclear, they are not routinely offered to the patients. Although the efficacy of these drop aids has not been well studied, if effective, the cost of these drop aids would more than pay themselves by improving medication compliance and visual function of the patients. This study aims to determine the efficacy of the Nanodropper in the BMC Yawkey Eye Clinic patient population.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Glaucoma Eye Diseases Intraocular Pressure Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

A randomized, crossover study design will be used to determine the efficacy of the Nanodropper in the BMC Yawkey Eye Clinic patient population. All participants will receive the Nanodropper, but will be randomly assigned to study groups defined by the order in which they use the Nanodropper. The first group will be assigned to use the drop aid device over the first 4-6 weeks, and then no drop aid device over the next 4-6 weeks. The second group will be assigned to use no drop aid device over the first 4-6 weeks, and then the drop aid device over the next 4-6 weeks. Therefore, each participant will undergo two study periods (using the drop aid and not using the drop aid).

Prior to use of the Nanodropper, participants will be instructed on how to use the drop aid by a member of the research team and a preintervention intraocular pressure check will be performed using an applanator which is part of the patient's standard of care. Intraocular pressure is the only adjustable risk factor for glaucoma; thus, glaucoma treatments slow progression of glaucoma by reducing intraocular pressure.

After 3 weeks and after at least 6 weeks per study period, participants will complete a satisfaction survey for the drop aid treatment group or control group. The 3 week satisfaction survey will take place over the phone. As part of routine eye care, participants will need to return to the clinic at least 6 week after enrollment. During this visit, a satisfaction survey will be completed, the participant's study diary will be collected, and routine intraocular pressure checks will be documented. If the participant does not complete the home study diary or forgets to bring it in to their appointment, a member of the study team will help them fill it out at a follow-up clinic appointment. The duration of participation for each subject will be 8-12 weeks.

The efficacy of the Nanodropper will be compared to the control and measured with any changes in intraocular pressure readings, length of time to medication completion, and patient satisfaction according to the surveys.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Currently on the same topical ophthalmic medications for treatment of glaucoma for a minimum of two months
  • Patient of Boston University Eye Associates

Exclusion criteria

  • Changed glaucoma medications within the past 2 months

Treatment and study plan

Nanodropper

Device

The Nanodropper is the only FDA-listed, volume-reducing adaptor for eyedrop bottles. By twisting the Nanodropper onto a compatible bottle, the drop-size can be reduced by over 60%. Smaller drops have been shown to reduce waste, cost, and side effects.

Other names: Drop aid

Primary outcomes

  1. Completion of topical ophthalmic drug bottle

    Time frame: 12 weeks

    This outcome will be measured in days by the patient from when a bottle is started until all the medication has been used.

  2. Satisfaction with dispensing opthalmic medication

    Time frame: 12 weeks

    An investigator developed survey completed by participants will be used to assess participants' satisfaction of eye drops with and without the drop aid.

Secondary outcomes

  1. Change in intraocular pressure with drop aid

    Time frame: before starting the drop aid, after 6 weeks of using the drop aid

    An applanator will be used to measure the intraocular pressure during standard of care appointments.

Study contacts

Contact information is provided by the study sponsor or research team.

Manishi Desai, MD

CONTACT

[email protected]

617 414 2020

Sreevardhan Alluri, MPH

CONTACT

[email protected]

617 414 8848

Sponsors and collaborators

Lead sponsor

Boston Medical Center

Other

Collaborators

  • Boston Medical Center Patient Safety Grant

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Feb 4, 2025
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.